Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility and Limitations of the Methyl Diaminobenzene-BODIPY Fluorescent Biosensor for Detecting Methylglyoxal in Cells.

ACS omega·2026
Same author

Myeloid HDAC7 drives liver inflammation and systemic glucose dysregulation during diet-induced obesity.

Clinical & translational immunology·2026
Same author

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria.

Medicinal research reviews·2026
Same author

Cytosolic delivery of bacterial metabolites by riboflavin transporters promotes MR1 antigen presentation and MAIT cell recognition.

Immunology and cell biology·2026
Same author

Experimental Evidence for a Metal-Related Function of a Cyanobactin.

Angewandte Chemie (International ed. in English)·2026
Same author

Mitochondrial fission mediates an evolutionarily conserved antibacterial defense response.

Science immunology·2026

Related Experiment Video

Updated: Jun 12, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

Selective hexapeptide agonists and antagonists for human complement C3a receptor.

Conor C G Scully1, Jade S Blakeney, Ranee Singh

  • 1Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia.

Journal of Medicinal Chemistry
|June 10, 2010
PubMed
Summary
This summary is machine-generated.

Researchers developed potent and selective small peptide agonists for human C3aR, a key receptor in innate immunity. These novel molecules offer potential as tools for studying immune responses and inflammatory diseases.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jun 12, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Area of Science:

  • Immunology
  • Pharmacology
  • Structural Biology

Background:

  • Human anaphylatoxin C3a is a critical innate immunity effector activating the C3a receptor (C3aR).
  • Existing peptide ligands for C3aR exhibit low potency or lack selectivity.

Purpose of the Study:

  • To develop the first potent and selective small peptide agonists for the human C3aR.
  • To explore structure-activity relationships for C3aR peptide ligands.
  • To create C3aR antagonists for research applications.

Main Methods:

  • Competitive binding assays using radiolabeled C3a and human peripheral blood mononuclear cells (PBMCs).
  • Intracellular calcium flux measurements to assess agonist/antagonist activity.
  • Receptor desensitization assays to monitor selectivity.
  • Nuclear Magnetic Resonance (NMR) spectroscopy to determine agonist structure.

Main Results:

  • Identified potent and selective small peptide agonists for human C3aR.
  • Determined the NMR structure of a C3aR agonist, revealing a beta-turn motif potentially crucial for binding and activation.
  • Developed a noncompetitive and insurmountable C3aR antagonist through derivatization.

Conclusions:

  • Novel small peptide agonists and antagonists for human C3aR have been developed.
  • These molecules represent valuable tools for investigating C3aR function in immunity and inflammatory diseases.
  • The identified beta-turn motif may guide future drug design for C3aR-targeted therapies.